Robert G. Wilcox

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

John Dormandy, B Charbonnel, D.J.A. Eckland et al. · The Lancet · 2005 · 4.1K citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +15

COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS

Robert Altman, L Carreras, Rubén Sierra Díaz et al. · Oxford University Research Archive (ORA) (University of Oxford) · 1994 · 3.3K citations

Medicine, Pharmacology, Pharmacotherapy +10

Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention

A. Michael Lincoff, John A. Bittl, Robert A. Harrington et al. · JAMA · 2003 · 1.2K citations

Medicine, Cardiology, Pharmacotherapy +17

TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION

Robert G. Wilcox, Carl Olsson, Allan M. Skene et al. · The Lancet · 1988 · 1.2K citations

Medicine, Cardiology, Internal Medicine +10

Predictors of Outcome in Patients With Acute Coronary Syndromes Without Persistent ST-Segment Elevation

Eric Boersma, Karen S. Pieper, Ewout W. Steyerberg et al. · Circulation · 2000 · 962 citations · Full text

Medicine, Cardiology, Internal Medicine +17